Experimental Gene Therapy Offers Hope to ALS Patient with Family History of the Disease

For 41-year-old Jeff Vierstra, the shadow of ALS—also known as Lou Gehrig’s disease—has loomed over his entire life. His mother succumbed to complications from the fatal neurodegenerative condition when he was just two years old. Decades later, his two sisters followed the same devastating path, both dying in their late 30s and early 40s after ALS robbed them of their mobility, speech, and ultimately their lives. Yet Vierstra, a scientist and lifelong adventurer, is defying that grim familial legacy through an experimental gene therapy being tested at Columbia University’s Eleanor and Lou Gehrig ALS Center. For the past three years, he has undergone spinal infusions designed to disable a mutated FUS gene—one that research has linked to an exceptionally high risk of developing ALS. While the treatment remains in early stages, preliminary results have left both Vierstra and his doctors cautiously optimistic: his muscle function has stabilized, and he has evaded the disease that has plagued every other member of his immediate family.

Why ALS Research Matters: The Devastating Impact of a Neurological Crisis

Amyotrophic lateral sclerosis (ALS) is more than a disease—it’s a neurological catastrophe that progressively dismantles a person’s ability to move, speak, and breathe. According to the Centers for Disease Control and Prevention, approximately 35,000 Americans are currently living with ALS, a condition that typically strikes between the ages of 40 and 70. The disease targets motor neurons, the cells responsible for transmitting signals from the brain and spinal cord to muscles. As these neurons degenerate and die, patients experience muscle weakness, twitching, and eventual paralysis. The average survival time after diagnosis is just two to five years, though some, like the late physicist Stephen Hawking, may live much longer with aggressive medical intervention. There is no cure. Existing treatments, such as the FDA-approved drug riluzole, only slow progression marginally, offering patients a few extra months of function.

Familial ALS: When Genetics Seal a Tragic Fate

While most ALS cases are sporadic—arising without a clear genetic cause—about 10 to 15% are hereditary, with the FUS gene mutation being one of the most aggressive and predictable culprits. In families like Vierstra’s, the mutation acts like a ticking clock. Dr. Neil Shneider, a neurologist at Columbia University and a leading researcher in genetic ALS, explains that familial ALS is often more severe and earlier-onset than sporadic cases. "About two-thirds of genetic ALS cases are familial," Shneider notes. "This means multiple generations are affected, and the disease tends to manifest in midlife, frequently before age 50." For families with a strong genetic predisposition, the psychological burden is immense. Vierstra describes the hereditary threat as a "cloud" that has shadowed his life: "Living with that sort of like cloud over you is like mentally and emotionally like really difficult."

A First-of-Its-Kind Prevention Trial Offers New Hope

In a groundbreaking shift from reactive treatment to proactive prevention, researchers at Columbia University are pioneering an experimental therapy aimed at disabling the mutated FUS gene before it can trigger ALS symptoms. The approach uses antisense oligonucleotides (ASOs), short strands of genetic material designed to bind to the faulty FUS gene and prevent it from producing toxic proteins that destroy motor neurons. Vierstra became one of the first participants in this trial after his sisters, Erin and Leigh, were diagnosed with ALS and enrolled in earlier phases of the study. Both sisters experienced rapid decline—Erin passed away in 2023 at age 39, and Leigh died in 2024 at age 41—leaving Vierstra as the sole surviving carrier of the mutation in his immediate family.

From Diagnosis to Prevention: The Science Behind the Therapy

The journey from diagnosis to prevention began when Dr. Shneider examined Vierstra using electromyography (EMG), a test that measures electrical activity in muscles. The results showed subtle abnormalities—early signs that ALS might be developing. "It was a difficult moment," Shneider recalls. "We thought this meant that this was an early sign of disease onset and that he was at risk for developing full blown disease." Rather than wait for symptoms to appear, Shneider offered Vierstra enrollment in the prevention trial. The treatment involves intrathecal infusions—direct injections into the spinal fluid—administered every few months. The goal is not just to treat ALS, but to stop it before it starts.

“I jumped at the opportunity to do that. I wanted to be proactive. I felt like this could extend their life, in a way—at least, give me more time to live without fear.”

After one year of treatment, Vierstra’s EMG results normalized, signaling that the therapy may have halted the disease’s progression before symptoms could take hold. While the treatment is not a cure and its long-term efficacy remains under study, the early results are unprecedented. Dr. Shneider calls the research "a very big deal," adding, "I think there’s real hope and opportunity to make this a livable disease, one that isn’t fatal."

Jeff Vierstra’s Story: A Life Lived Against the Odds

Vierstra’s resilience is as much a part of his story as the science behind his treatment. A scientist by training, he has spent years studying genetics and neuroscience—fields that now intersect with his own life in a deeply personal way. Yet his passions extend far beyond the lab. He’s an avid skier, having tackled treacherous slopes in Chile and British Columbia, and a world traveler who finds solace in the outdoors. "And maybe this actually is working for me and I can start thinking about the future, and I otherwise couldn’t have," he reflects. For someone who has spent his life defying limits—both on the mountain and in the lab—Vierstra now finds himself defying a genetic death sentence. His ability to continue working, traveling, and enjoying life is a testament to the potential of preventive medicine, even in the face of a disease as relentless as ALS.

The Broader Implications: Can Gene Therapy Transform ALS Treatment?

While Vierstra’s case involves a rare genetic form of ALS, researchers at Columbia and beyond are hopeful that the lessons learned from FUS-ALS prevention could eventually extend to more common, sporadic forms of the disease. Dr. Shneider and his team are already expanding their work through the Silence ALS initiative, a Columbia University-led effort to develop individualized gene-based therapies for patients with other rare genetic forms of ALS. The goal is to create a pipeline of treatments that can be tailored to specific mutations, much like precision medicine in oncology. "We’re learning how to intervene earlier," Shneider says. "If we can prevent the disease from ever taking hold, we change the entire trajectory of a patient’s life."

Key Takeaways: What This Research Means for Patients and Families

• Jeff Vierstra is participating in the first known attempt to prevent ALS using gene therapy targeting a mutated FUS gene.
• About 10-15% of ALS cases are genetic, with familial forms often striking earlier and more aggressively than sporadic cases.
• Early results from Vierstra’s treatment show stabilized muscle function, offering cautious optimism for disease prevention.
• Columbia University’s Silence ALS initiative aims to expand gene therapy research to other rare genetic forms of ALS.
• While not a cure, the therapy represents a paradigm shift from treating ALS symptoms to preventing them entirely.

The Road Ahead: Challenges and Unanswered Questions

Despite the promise of Vierstra’s case, significant challenges remain. Gene therapies like the one he’s receiving are expensive, complex to administer, and require long-term monitoring for side effects. Additionally, not all patients with genetic ALS may respond the same way to treatment, and the therapy’s durability over decades is still unknown. Ethical questions also arise: Should preventive treatments be offered to asymptomatic carriers of high-risk mutations? How do families weigh the psychological toll of living with a genetic death sentence against the hope of intervention? For now, Vierstra’s story serves as both a beacon of hope and a reminder of how much work remains. "I feel like I’m getting another lease of life," he says. "And that’s not something I ever thought I’d say."

How to Learn More or Participate in ALS Research

For individuals or families affected by ALS—particularly those with known genetic mutations—the Eleanor and Lou Gehrig ALS Center at Columbia University offers multiple avenues for participation in ongoing research. The Silence ALS initiative is actively recruiting patients with rare genetic forms of the disease to explore individualized gene-based therapies. Interested individuals can contact the program directly via email at silenceals@cumc.columbia.edu. Additionally, organizations like the ALS Association and the Muscular Dystrophy Association provide resources, clinical trial databases, and support for patients navigating treatment options.

Frequently Asked Questions About ALS Gene Therapy and Prevention